Investment Rating - The report maintains a "Buy" rating for the company with a target price of HK$195.16, representing a potential upside of 32% from the current price of HK$147.70 [2][10][17]. Core Insights - The company achieved its first GAAP profit in Q1 2025, with revenue growth and pipeline realization creating a positive cycle. The revenue for 2024 was reported at US$3.81 billion, a 55% year-on-year increase, and the company reported a net loss of US$645 million, narrowing by 27% [7][11]. - The main product, Zebutini, saw Q1 2025 sales reach US$792 million, a significant increase of 62.1% year-on-year, indicating a strong commercialization foundation [8]. - The R&D pipeline is progressing well, with several products in critical clinical stages, including the BCL-2 inhibitor Sonrotoclax and BTK CDAC (BGB-16673), which are expected to yield important clinical results soon [9]. Financial Summary - The company’s revenue is projected to grow from US$3.81 billion in 2024 to US$5.39 billion in 2025, with a net profit expected to turn positive at US$93 million in 2025 [12][13]. - The report indicates a decrease in EPS estimates for 2025 and 2026, revised to US$0.06 and US$0.37 respectively, reflecting a 39% and 29% reduction from previous estimates [3][13]. - The financial data shows a significant improvement in operating cash flow, with Q1 2025 cash inflow reaching US$44.08 million, indicating enhanced operational efficiency [7][12]. Product Performance - The core product, Baiyueze, is expected to generate sales of US$3.31 billion in 2025, a 43.3% increase from previous estimates, while other products are projected to contribute US$0.81 billion [14][16]. - The report highlights that the company’s revenue structure is increasingly concentrated on core products, supported by ongoing expansion in overseas markets [14]. Valuation Analysis - The DCF model used for valuation indicates a target price of HK$195.16, based on a WACC of 8.1% and a perpetual growth rate of 4.5% [17][19]. - The company’s projected enterprise value/revenue for 2025 is 5.5 times, which is below the industry average of 8.1 times, suggesting that the market has not fully recognized the company’s strong commercialization capabilities [18].

Investment Rating - The report initiates coverage with a "Buy" rating for Horizon Robotics, setting a target price of HK$8.60, representing a potential upside of 33% from the current price of HK$6.46 [1][6][10]. Core Insights - Horizon Robotics is positioned as a key beneficiary in the high-end assisted driving industry, with a strong market share exceeding 40% in China's OEM advanced driver assistance systems (ADAS) market as of 2024 [7][29]. - The company is expected to benefit significantly from the global growth potential of smart driving, with projections indicating that global and Chinese smart vehicle sales will reach approximately 80 million and 30 million units by 2030, respectively [7][29]. - The unique BPU (Brain Processing Unit) architecture of Horizon Robotics provides a competitive edge by optimizing hardware and software collaboration, achieving higher computational efficiency at lower power consumption [30][42]. Financial Projections - Revenue forecasts for Horizon Robotics are projected at RMB 3.43 billion, RMB 5.41 billion, and RMB 7.46 billion for the years 2025, 2026, and 2027, respectively, reflecting year-on-year growth rates of 43.7%, 57.9%, and 37.9% [9][31]. - The company is expected to achieve profitability in 2027, with a projected net profit of RMB 901 million, following losses in the preceding years [9][31]. Market Comparison - The report compares Horizon Robotics with peers such as NVIDIA, ARM, Mobileye, and Black Sesame Intelligence, applying a 20x price-to-sales (P/S) ratio to derive the target price [32][71]. - The competitive landscape indicates that Horizon Robotics has established itself as a leader in the mid-to-low-end smart driving hardware market, with plans to penetrate the high-end market further with the launch of the Journey 6 series chips [71][72]. Product Solutions - Horizon Robotics offers three main smart driving solutions: Horizon Mono, Horizon Pilot, and Horizon SuperDrive, catering to different levels of driving assistance [44][60]. - The Journey 6 series chips, set to launch in 2025, will cover a wide range of smart driving needs, enhancing the company's product matrix [62][67].

研究报告 Research Report 23 Jun 2025 珍酒李渡 ZJLD (6979 HK) 珍酒李渡跟踪报告：立足长远，前瞻布局 Take a Long-term Perspective and Plan Ahead [Table_yemei1] 观点聚焦 Investment Focus [Table_Info] 维持优于大市 Maintain OUTPERFORM 评级 优于大市 OUTPERFORM 现价 HK$6.16 目标价 HK$8.80 HTI ESG 0.9-1.3-3.0 E-S-G: 0-5, (Please refer to the Appendix for ESG comments) 市值 HK$20.87bn / US$2.66bn 日交易额 (3 个月均值) US$5.85mn 发行股票数目 3,389mn 自由流通股 (%) 31% 1 年股价最高最低值 HK$10.34-HK$5.71 注：现价 HK$6.16 为 2025 年 06 月 20 日收盘价 资料来源： Factset 1mth 3mth 12mth 绝对值 -8.7% -16.8% -23.1% 绝 ...

Investment Rating - The investment rating for the company is "Buy" with a target price of 1.14 HKD [6][7]. Core Views - The company is expected to report a net loss of 800-1,000 million RMB for the first half of 2025, compared to a net loss of 210 million RMB in the same period last year. The apparent profit loss is primarily due to impairment and other non-cash items, while actual operations remain stable [1][2]. - The company is actively improving its herd structure and controlling operational costs, with a slight expected decrease in the total number of dairy cows by the end of the first half of 2025, while raw milk sales volume is projected to increase by approximately 10% year-on-year [1][2]. - The company anticipates a reduction in feed costs and other cash costs in the second half of 2025, which may alleviate impairment pressures and allow for profit recovery [1][2]. Summary by Sections Financial Performance - The company expects to report a cash EBITDA for the first half of 2025 that is roughly comparable to the previous year, despite the apparent profit loss due to non-cash impairment losses estimated at 1,650-1,850 million RMB, an increase of 500-700 million RMB year-on-year [2][4]. - Revenue projections for 2025-2027 indicate a slight recovery, with expected net profits of -1,313 million RMB in 2025, 658 million RMB in 2026, and 1,117 million RMB in 2027, reflecting a significant turnaround [4][5]. Market Dynamics - The current dairy price adjustments are driven by supply-demand mismatches, with the company indicating a clear direction towards capacity reduction in response to prolonged low milk prices [3]. - The company is expected to see a decrease in its breeding stock in 2025, reflecting the industry's response to market conditions, with a notable increase in the proportion of productive cows [3]. Valuation Metrics - The target price of 1.14 HKD corresponds to a 13x PE ratio for 2026, down from a previous target of 1.35 HKD, indicating a cautious outlook due to ongoing impairment losses [4][6]. - The company's estimated EPS for 2025 is -0.17 RMB, with projections of recovery to 0.08 RMB in 2026 and 0.14 RMB in 2027, suggesting a potential for profit growth in the coming years [5][12].

Investment Rating - The investment rating for the company is "Buy" and is maintained [15] Core Viewpoints - The report emphasizes the company's IP strategy as a means to reshape its business model and create a new growth engine, focusing on "interest consumption" to drive brand upgrades and business growth [10][13][24] Summary by Sections Strategic Goals - The company's IP strategy aims to upgrade channel positioning, transitioning from a cost-effective retailer to an IP retail collection store, tapping into the significant growth opportunities within the Chinese IP retail market [10][23] Competitive Advantages - The company benefits from high-frequency product iteration and a global network layout, with inventory turnover days at 50 days, significantly lower than peers, and a strong design team with 124 internal designers and 37 international designers [11][57] Growth Path - The company focuses on high emotional value "super categories" such as plush toys and blind boxes, enhancing terminal presentation through a seven-layer store matrix, with the highest level being MINISO LAND, which showcases top IP products [12][57] Investment Recommendations - The report forecasts that the company's adjusted net profit will reach 2.9 billion, 3.27 billion, and 4.15 billion yuan from 2025 to 2027, indicating a positive outlook for its IP retail market development [13][19]

证券研究报告·海外公司深度·旅游及消闲设施(HS) 小菜园（00999.HK） "好吃便宜"大众便民中餐，强激励助推强 势扩张 买入（首次） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 4,549 | 5,210 | 6,219 | 7,572 | 9,192 | | 同比(%) | 41.58 | 14.52 | 19.37 | 21.75 | 21.39 | | 归母净利润（百万元） | 532.06 | 580.62 | 709.89 | 878.47 | 1,119.39 | | 同比(%) | 123.96 | 9.13 | 22.26 | 23.75 | 27.42 | | EPS-最新摊薄（元/股） | 0.45 | 0.49 | 0.60 | 0.75 | 0.95 | | P/E（现价&最新摊薄） | 16.40 | 15.03 | 12.29 | 9.93 | 7.80 | [Table_Tag] [T ...

Investment Rating - The investment rating for Xiaomi Group is "Buy" with a target price not specified in the report [3][4]. Core Viewpoints - The report emphasizes that the YU7 model is expected to be a significant product for Xiaomi, showcasing a shift towards practicality while maintaining a luxurious brand image. The YU7 is positioned as a mid-to-large pure electric SUV, featuring advanced technology such as laser radar, 800V fast charging, and Nvidia Thor chips [1][2]. - The YU7 is anticipated to leverage Xiaomi's ecosystem, potentially enhancing overall revenue growth through better integration with AIOT products. The initial user interest has exceeded expectations, with a significant portion of new users showing interest in the brand [2][3]. - The report forecasts a strong sales performance for the YU7, predicting that it may outperform market expectations due to its competitive pricing strategy and high-value features [3]. Summary by Sections Product Overview - The YU7 is Xiaomi's second vehicle, designed to complement the SU7, with a focus on a more practical approach while retaining a sporty design. It offers options for single and dual motor configurations, with a 0-100 km/h acceleration time of 3.23 seconds [1]. Market Positioning - The YU7's pricing strategy is centered around providing value for money, with luxury features included in the offering. The report notes that the initial user engagement for the YU7 has been significantly higher than that of the SU7, indicating a broader appeal [2][3]. Financial Projections - The report projects that Xiaomi's total revenue could reach 471.8 billion CNY in 2025 and 679.7 billion CNY in 2026, with electric vehicles and innovative business segments contributing 96.4 billion CNY and 250.6 billion CNY respectively. The adjusted net profit is expected to be 42.9 billion CNY and 85.5 billion CNY for the same years [3].

Investment Rating - The report assigns a "Buy" rating for the company, with an initial coverage forecast for net profit attributable to the parent company reaching 1.01 billion, 1.23 billion, and 1.45 billion yuan for the years 2025 to 2027 respectively [12][13]. Core Insights - The company, as one of the earliest established Chinese cosmetics firms, has achieved cyclical growth through strong channel and marketing capabilities, supported by a mature supply chain and deep in-house research and development capabilities [5][12]. - The main brand, Han Shu, is expanding its product categories and channels, with a focus on high-priced single products and reducing reliance on high-fee Douyin channels, which is expected to improve sales structure and contribute to revenue and performance elasticity [5][12]. - The sub-brands are well diversified, with the mother and baby brand Newpage showing strong growth, indicating potential for long-term group expansion [5][12]. Summary by Sections Company Overview - The company is a leading multi-brand cosmetics firm in China, covering various categories including skincare, maternal and infant care, hair care, and makeup, with a price range from mass-market to high-end [9][21]. - The main brand, Han Shu, is projected to achieve a revenue of 5.6 billion yuan in 2024, accounting for 82% of total revenue [21][23]. Development Review - The company's growth can be divided into four phases: 1. Startup Phase (2003-2007) and Rapid Growth Phase (2008-2018) where it leveraged offline stores and emerging channels to establish its brand. 2. Adjustment Phase (2019-2022) where it faced challenges due to channel and consumer concept changes, leading to a brand repositioning. 3. Transformation Breakthrough Phase (2023-present) where it successfully capitalized on the Douyin live-streaming e-commerce trend, revitalizing the Han Shu brand [10][33]. Growth Potential - The main brand is entering a stable growth phase, with future revenue growth expected from category expansion into high-priced products and channel diversification beyond Douyin [11][12]. - The sub-brands are positioned to support long-term group expansion, with a comprehensive product matrix that enhances the company's competitive edge in the cosmetics market [11][12]. Investment Recommendations - The report emphasizes the optimization of Han Shu's sales structure and the contribution of sub-brands to the company's long-term growth potential, projecting significant profit growth in the coming years [12][23].

Investment Rating - The report initiates coverage with a "Buy" rating for the company [2] Core Views - The company reported a revenue of HKD 896.56 billion for the fiscal year 2025, a year-on-year decrease of 17.5%, while the net profit attributable to shareholders was HKD 59.16 billion, down 8.98%. Excluding the impact of gold lending, the operating profit was HKD 147.46 billion, an increase of 9.8% year-on-year [5][6] - The company is expected to benefit from the recovery in the gold jewelry industry starting from Q2 2025, with a strong growth outlook in the medium to long term due to the trend of self-consumption and the increasing demand for jewelry [11] Summary by Sections Company Overview - Latest closing price: HKD 12.76 - Total shares: 9.988 billion - Total market capitalization: HKD 1,274.44 billion - 52-week high/low: HKD 13.72 / HKD 6.43 - Debt-to-asset ratio: 69.89% - Price-to-earnings ratio: 22.15 [4] Market Analysis - The company experienced a revenue decline of 17.5% in FY2025, with mainland China sales at HKD 746 billion (down 17%) and Hong Kong/Macau at HKD 151 billion (down 21%) [6] - Same-store sales in mainland China showed a gradual improvement, with declines narrowing from -26% to -13% over the fiscal year [7] Product Analysis - The sales of priced gold products doubled, while traditional gold products saw a decline of 29.4%. The share of priced gold products increased from 19% in 2024 to 29% in 2025 [10] - The "Heritage" series has become a best-seller, contributing significantly to sales, with new product lines launched in 2024 and 2025 exceeding annual targets [10] Profitability Analysis - The operating profit for FY2025 was HKD 147.46 billion, reflecting a 9.8% increase year-on-year. The gross margin improved by 550 basis points to 29.5% due to high-margin products and strict cost control [10] Investment Recommendations and Earnings Forecast - The company is projected to achieve revenue growth rates of 3.3%, 5.5%, and 4.2% for FY2026 to FY2028, with net profit growth rates of 19%, 16%, and 7% respectively. The expected EPS for these years are HKD 0.71, 0.82, and 0.88, with corresponding P/E ratios of 18x, 16x, and 14x [11][14]

Investment Rating - The report assigns a "Buy" rating for the company for the first time [3][9]. Core Views - The company is a leading player in the global monosodium glutamate (MSG) industry, with production capacity expected to reach 173,000 tons per year by the end of 2024, making it the largest globally [6][15]. - The demand for MSG is anticipated to grow, with the industry expected to hit a bottom and recover as new capacities are absorbed [3][9]. - The company is also a leader in feed amino acids, benefiting from an improving industry landscape and increasing demand, alongside its proactive overseas expansion efforts [3][9]. Company Overview - The company focuses on fermentation products, with a diverse product line including MSG, lysine, threonine, and xanthan gum [6][15]. - By the end of 2023, the company's MSG production capacity was 1.33 million tons per year, projected to increase to 1.65 million tons by the end of 2024 [6][15]. - The company has maintained a dividend payout ratio of 33%-35% from 2018 to 2021, with a forecasted payout ratio of 35% plus a special dividend from 2022 to 2024 [6][25]. Financial Summary - The company has shown steady growth, with a compound annual growth rate (CAGR) of 11.0% in revenue and 6.4% in net profit from 2010 to 2024 [28]. - In 2024, the company is expected to generate revenue of 27.76 billion yuan, a year-on-year decrease of 1.3%, and a net profit of 2.31 billion yuan, down 26.5% year-on-year [28][30]. - The company's gross profit margin for 2024 is projected to be 18.2%, with a net profit margin of 8.3% [34]. Industry Insights - The MSG industry is characterized by high concentration, with China accounting for approximately 70% of global consumption and 80.3% of global production capacity by 2024 [7][51]. - The demand for lysine and threonine is expected to grow, particularly in emerging markets, driven by increased feed production and the adoption of low-protein diets [59][63]. - The company is well-positioned to benefit from the ongoing shift in the amino acid industry towards domestic production and the rising demand in developing regions [63][64].